These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33372585)

  • 81. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
    Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
    Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
    Casadei-Gardini A; Vagheggini A; Gelsomino F; Spallanzani A; Ulivi P; Orsi G; Rovesti G; Andrikou K; Tamburini E; Scartozzi M; Cascinu S
    Clin Colorectal Cancer; 2020 Jun; 19(2):82-90.e9. PubMed ID: 32192883
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
    Hsu HC; Huang KC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang TS; Chen CC; Chao Y; Teng HW
    Sci Rep; 2021 Jul; 11(1):15370. PubMed ID: 34321583
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.
    Roberto M; Falcone R; Mazzuca F; Archibugi L; Castaldi N; Botticelli A; Osti MF; Marchetti P
    Medicine (Baltimore); 2017 Dec; 96(48):e9023. PubMed ID: 29310420
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.
    Pimenta JR; Racy DJ; Zapata LM; D'Alpino Peixoto R
    J Gastrointest Cancer; 2021 Jun; 52(2):784-787. PubMed ID: 32944848
    [No Abstract]   [Full Text] [Related]  

  • 88. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.
    Fujita K; Taguchi D; Fukuda K; Yoshida T; Shimazu K; Shinozaki H; Shibata H; Miura M
    Invest New Drugs; 2024 Jun; 42(3):252-260. PubMed ID: 38517650
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [A Case of Unresectable Recurrent Colorectal Cancer with Regorafenib Treatment and Long-Term Survival].
    Maruo H; Sato S; Nakamura T; Sekimori K; Obayashi M; Hayashi Y; Ishimatsu H; Shoji T; Hirayama K; Yamazaki M
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1670-1672. PubMed ID: 35046292
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
    Rechsteiner M; Wild P; Kiessling MK; Bohnert A; Zhong Q; Stahel RA; Moch H; Curioni-Fontecedro A
    Ann Oncol; 2015 Jan; 26(1):246-248. PubMed ID: 25336117
    [No Abstract]   [Full Text] [Related]  

  • 91. Intestinal perforation after regorafenib usage.
    Sarıcı B; Karakaş S; Uylas U; Aktaş A; Dikilitaş M; Kayaalp C
    Turk J Gastroenterol; 2018 Mar; 29(2):245-247. PubMed ID: 29749339
    [No Abstract]   [Full Text] [Related]  

  • 92. Regorafenib-induced Myopathy.
    Ochiai S; Ueno T; Igarashi S; Arai A
    Intern Med; 2024 Aug; 63(16):2343-2344. PubMed ID: 38220194
    [No Abstract]   [Full Text] [Related]  

  • 93. Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature.
    Bellia MA; Sofia C; Marino MA; Mazzeo C; Biondo SA; Cucinotta E; Fleres F
    Radiol Case Rep; 2024 May; 19(5):2013-2019. PubMed ID: 38449482
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Two Cases of the Significant Liver Damage by Regorafenib].
    Machida T; Yoshida M; Saiga H; Koide T; Matsumoto A; Wada T; Tanaka H; Harada N; Mitsutsuji M; Samizo M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1600-1602. PubMed ID: 38303354
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report.
    Zhang G; Lin L; Dong D; Qiu H; Liu T; Lian L; Shen G
    Medicine (Baltimore); 2021 Jan; 100(4):e24295. PubMed ID: 33530218
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
    Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
    J Am Acad Dermatol; 2024 Feb; 90(2):368-369. PubMed ID: 37690021
    [No Abstract]   [Full Text] [Related]  

  • 97. New oral lesion by regorafenib: A case report.
    Spirito F; Caggiano M; Sisalli L; Di Spirito F; Amato M
    Oral Dis; 2023 Jan; 29(1):337-338. PubMed ID: 35403798
    [No Abstract]   [Full Text] [Related]  

  • 98. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
    Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
    J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
    Nakashima M; Takeuchi M; Tanaka S; Kawakami K
    Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.